2009
DOI: 10.1055/s-0029-1216368
|View full text |Cite
|
Sign up to set email alerts
|

‘In Silico’ Oncology for Clinical Decision Making in the Context of Nephroblastoma

Abstract: The present paper outlines the initial version of the ACGT (Advancing Clinico-Genomic Trials) -- an Integrated Project, partly funded by the EC (FP6-2005-IST-026996)I-Oncosimulator as an integrated software system simulating in vivo tumour response to therapeutic modalities within the clinical trials environment aiming to support clinical decision making in individual patients. Cancer treatment optimization is the main goal of the system. The document refers to the technology of the system and the clinical req… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
24
0

Year Published

2009
2009
2015
2015

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 18 publications
(24 citation statements)
references
References 37 publications
0
24
0
Order By: Relevance
“…A “top-down” simulation approach is formulated [25], [26]; the method starts from the macroscopic imaging data (a high biocomplexity level) and proceeds towards lower biocomplexity levels. When there is a need for an upwards movement in the biocomplexity scales, a summary of the available information pertaining to the previous lower level is used.…”
Section: Methodsmentioning
confidence: 99%
“…A “top-down” simulation approach is formulated [25], [26]; the method starts from the macroscopic imaging data (a high biocomplexity level) and proceeds towards lower biocomplexity levels. When there is a need for an upwards movement in the biocomplexity scales, a summary of the available information pertaining to the previous lower level is used.…”
Section: Methodsmentioning
confidence: 99%
“…For instance, in clinico-genomic research gene expression patterns are generated before, during and after treatment in order to study the patient's gene activity in response to therapy. The final goal of clinico-genomic research is to identify significant biological markers associated with the development of disease and its response to treatment 20 21. However, a direct benefit for the patient is possible but not generally expected 22–24…”
Section: Introductionmentioning
confidence: 99%
“…By the end of the ACGT project some 7000 simulations had been run using the ORS; early results of this work were published in [21] and [22], [23]. In general, the simulator was shown to be robust and predictable across a broad range of parameter settings, but the ability to make comparisons did help to discover various unexpected behaviors that the simulator developers were then able to resolve.…”
Section: Subjunctive Interface System For the Exploration Of The mentioning
confidence: 99%